Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    CareDx, Inc (CDNA)

    Price:

    12.17 USD

    ( + 0.60 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    CDNA
    Name
    CareDx, Inc
    Industry
    Medical - Diagnostics & Research
    Sector
    Healthcare
    Price
    12.170
    Market Cap
    647.771M
    Enterprise value
    1.044B
    Currency
    USD
    Ceo
    John Walter Hanna Jr.
    Full Time Employees
    644
    Website
    Ipo Date
    2014-07-17
    City
    South San Francisco
    Address
    1 Tower Place

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    IDEXX Laboratories, Inc.

    VALUE SCORE:

    8

    Symbol
    IDXX
    Market Cap
    51.097B
    Industry
    Medical - Diagnostics & Research
    Sector
    Healthcare

    2nd position

    GRAIL, Inc.

    VALUE SCORE:

    9

    Symbol
    GRAL
    Market Cap
    1.145B
    Industry
    Medical - Diagnostics & Research
    Sector
    Healthcare

    The best

    Medpace Holdings, Inc.

    VALUE SCORE:

    9

    Symbol
    MEDP
    Market Cap
    13.116B
    Industry
    Medical - Diagnostics & Research
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    12.788
    P/S
    1.901
    P/B
    2.019
    Debt/Equity
    0.070
    EV/FCF
    33.750
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    1.767
    Earnings yield
    0.078
    Debt/assets
    0.051
    FUNDAMENTALS
    Net debt/ebidta
    1.298
    Interest coverage
    0
    Research And Developement To Revenue
    0.204
    Intangile to total assets
    0.172
    Capex to operating cash flow
    0.007
    Capex to revenue
    0.000
    Capex to depreciation
    0.006
    Return on tangible assets
    0.140
    Debt to market cap
    0.035
    Piotroski Score
    4.000
    FUNDAMENTALS
    PEG
    -1.239
    P/CF
    37.292
    P/FCF
    36.296
    RoA %
    11.633
    RoIC %
    11.265
    Gross Profit Margin %
    49.874
    Quick Ratio
    2.998
    Current Ratio
    3.298
    Net Profit Margin %
    15.163
    Net-Net
    2.465
    FUNDAMENTALS PER SHARE
    FCF per share
    0.329
    Revenue per share
    6.276
    Net income per share
    0.952
    Operating cash flow per share
    0.326
    Free cash flow per share
    0.329
    Cash per share
    3.430
    Book value per share
    6.028
    Tangible book value per share
    4.622
    Shareholders equity per share
    6.028
    Interest debt per share
    0.419
    TECHNICAL
    52 weeks high
    33.210
    52 weeks low
    10.960
    Current trading session High
    12.410
    Current trading session Low
    11.272
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Diagnostics & Research
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -59.899
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.781
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Diagnostics & Research
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -17.556
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.170
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Diagnostics & Research
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -86.612
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Diagnostics & Research
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -4.483
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Diagnostics & Research
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -18.579
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    87.640
    DESCRIPTION

    CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

    NEWS
    https://images.financialmodelingprep.com/news/caredx-cdna-eps-beats-sales-gain-14-20250806.jpg
    CareDx (CDNA) EPS Beats Sales Gain 14%

    fool.com

    2025-08-06 23:42:58

    CareDx (CDNA) EPS Beats Sales Gain 14%

    https://images.financialmodelingprep.com/news/caredx-inc-cdna-q2-2025-earnings-call-transcript-20250806.jpg
    CareDx, Inc (CDNA) Q2 2025 Earnings Call Transcript

    seekingalpha.com

    2025-08-06 22:47:14

    CareDx, Inc (NASDAQ:CDNA ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Abhishek Jain - CFO & Principal Accounting Officer Caroline Corner - Corporate Participant John Walter Hanna - President, CEO & Director Keith S. Kennedy - Chief Operating Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Mark Anthony Massaro - BTIG, LLC, Research Division Tycho W.

    https://images.financialmodelingprep.com/news/heres-what-key-metrics-tell-us-about-caredx-cdna-20250806.jpg
    Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings

    zacks.com

    2025-08-06 19:32:26

    The headline numbers for CareDx (CDNA) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

    https://images.financialmodelingprep.com/news/caredx-cdna-lags-q2-earnings-and-revenue-estimates-20250806.jpg
    CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates

    zacks.com

    2025-08-06 18:45:35

    CareDx (CDNA) came out with quarterly earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.25 per share a year ago.

    https://images.financialmodelingprep.com/news/caredx-announces-appointment-of-nathan-smith-as-chief-financial-20250806.jpg
    CareDx Announces Appointment of Nathan Smith as Chief Financial Officer

    businesswire.com

    2025-08-06 16:57:00

    BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth p.

    https://images.financialmodelingprep.com/news/caredx-announces-second-quarter-2025-financial-results-20250806.jpg
    CareDx Announces Second Quarter 2025 Financial Results

    businesswire.com

    2025-08-06 16:01:00

    BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company - a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Reported revenue of $86.7 million including a $3.8 million write-off of aged receivables ass.

    https://images.financialmodelingprep.com/news/caredx-announces-landmark-koar-study-published-in-the-american-20250806.jpg
    CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation

    businesswire.com

    2025-08-06 12:56:00

    BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the publication of the Kidney Allograft Outcomes AlloSure Registry (KOAR) study in the American Journal of Transplantation. The landmark prospective study demonstrates the clinical utility of.

    https://images.financialmodelingprep.com/news/caredx-announces-landmark-data-in-aipowered-transplant-diagnostics-showcased-in-20250731.jpg
    CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress

    businesswire.com

    2025-07-31 16:01:00

    BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the presentation of several high-impact studies and digital health innovations by independent research teams at the 2025 World Transplant Congress (WTC), demonstrating advances in artificial.

    https://images.financialmodelingprep.com/news/caredx-to-report-second-quarter-2025-financial-results-20250723.jpg
    CareDx to Report Second Quarter 2025 Financial Results

    businesswire.com

    2025-07-23 07:05:00

    BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the second quarter 2025 after market close on Wednesday, August 6, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Tim.

    https://images.financialmodelingprep.com/news/caredx-cdna-surges-70-is-this-an-indication-of-20250722.jpg
    CareDx (CDNA) Surges 7.0%: Is This an Indication of Further Gains?

    zacks.com

    2025-07-22 08:10:15

    CareDx (CDNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

    https://images.financialmodelingprep.com/news/caredx-announces-proposed-draft-lcd-that-affirms-surveillance-testing-20250718.jpg
    CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection

    businesswire.com

    2025-07-18 08:00:00

    BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – announced the release of a proposed draft Local Coverage Determination (LCD) related to molecular testing for solid organ allograft rejection. There is no change in current coverage and the draft LCD is open.

    https://images.financialmodelingprep.com/news/caredx-the-transplant-diagnostics-leader-but-challenges-will-increase-20250614.jpg
    CareDx: The Transplant Diagnostics Leader, But Challenges Will Increase On The Road Ahead

    seekingalpha.com

    2025-06-14 07:23:41

    CareDx has a unique, comprehensive organ transplant diagnostics portfolio and maintains strong revenue growth, but faces intensifying competition and regulatory risks. Recent legal resolutions and operational improvements have strengthened the investment case, yet the company has never achieved operating profitability, raising concerns. Future growth depends on successful new product launches and expanding its ecosystem, but ongoing innovation is required to stay ahead of AI-driven competitors.

    https://images.financialmodelingprep.com/news/caredx-announces-repurchase-of-5-of-outstanding-shares-20250603.jpg
    CareDx Announces Repurchase of 5% of Outstanding Shares

    businesswire.com

    2025-06-03 16:30:00

    BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has completed the repurchase of $50 million of its common stock representing approximately 5% of outstanding shares. The share repurchase follows the completion of the company's seven.

    https://images.financialmodelingprep.com/news/johnson-fistel-has-commenced-an-investigation-on-behalf-of-caredx-20250522.jpg
    Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders

    businesswire.com

    2025-05-22 09:27:00

    SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 30, 2020 and February 24, 2022, certain CareDx insiders caused the company to issue false and misleading public statements regarding its compliance with health.

    https://images.financialmodelingprep.com/news/johnson-fistel-has-commenced-an-investigation-on-behalf-of-20250521.jpg
    Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders

    globenewswire.com

    2025-05-21 20:48:00

    SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for potential breaches of fiduciary duties and violations of the federal securities laws.

    https://images.financialmodelingprep.com/news/caredx-to-participate-in-upcoming-investor-conferences-20250513.jpg
    CareDx to Participate in Upcoming Investor Conferences

    businesswire.com

    2025-05-13 16:01:00

    BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences. Craig-Hallum 22nd Annual Institutional Investor Conference in Minneapolis, MN on Wednesday, May 28. Jefferies Global Health.